PMID: 6412893Oct 1, 1983Paper

Role of hepatic arterial embolisation in the carcinoid syndrome

British Medical Journal
P N MatonV S Chadwick

Abstract

Eighteen patients with severe symptoms of the carcinoid syndrome were assessed for hepatic embolisation. Four were too ill, and one had mild symptoms; thus 13 received a periembolisation regimen of cyproheptadine, fenclonine, aprotinin, methylprednisolone, tobramycin, flucloxacillin, and metronidazole. Embolisation was not performed in one patient with an occluded portal vein and was unsatisfactory in two others, in one because she was moribund and in the other because the hepatic artery had been ligated. Dramatic improvement in symptoms occurred in the nine patients in whom embolisation was successfully carried out, with abolition of flushing, severe abdominal pain, and wheeze and reduction in diarrhoea from 10.5 (SD 7.6) to 1.6 (0.9) stools/day. Urinary excretion of 5-hydroxyindole acetic acid fell from 1048 (716) to 289 (184) mumol/24 h (200 (137) to 55 (35) mg/24 h). Complications included one death from septicaemia, a hepatic abscess requiring surgical drainage, abdominal pain in three patients, pleural effusion in two, and transient encephalopathy in one. Relief of symptoms lasted for one to 24 months, and second embolisation in two patients produced further remissions of four to six months. Five patients died, one to 40 ...Continue Reading

References

Apr 1, 1972·Archives of Dermatology·R J Castiello, P J Lynch
May 2, 1974·The New England Journal of Medicine·E T Mays, C S Wheeler
May 1, 1971·Canadian Anaesthetists' Society Journal·R Déry

❮ Previous
Next ❯

Citations

Jan 1, 1990·Cardiovascular Drugs and Therapy·J I Robertson
Mar 1, 1989·Digestive Diseases and Sciences·A Vinik, A R Moattari
Dec 1, 1985·World Journal of Surgery·H F WoodsJ A Smith
Jun 1, 1988·World Journal of Surgery·H AhlmanL E Tisell
Mar 1, 1997·Diseases of the Colon and Rectum·P C NearyD Bouchier-Hayes
Jan 1, 1987·Cardiovascular and Interventional Radiology·D L Miller
Sep 3, 2004·Current Treatment Options in Oncology·Jonathan Whisenant, Alan Venook
Mar 18, 1999·The New England Journal of Medicine·M H Kulke, R J Mayer
Jan 23, 1999·Current Opinion in Oncology·A P Venook
Nov 12, 1988·BMJ : British Medical Journal·H J Hodgson
Jan 1, 1995·Annual Review of Medicine·J B Meko, J A Norton
Mar 1, 1990·Baillière's Clinical Endocrinology and Metabolism·S W LambertsJ C Reubi
Jul 1, 1989·Current Problems in Cancer·N Kemeny, A Schneider
May 1, 1988·European Journal of Cancer & Clinical Oncology·C P Delcour, J L Struyven
Jan 1, 1989·Acta Oncologica·H AhlmanL E Tisell
Jul 1, 1985·The British Journal of Surgery·I Taylor
Jan 5, 2019·Endocrine-related Cancer·Johannes HoflandWouter W de Herder
Sep 27, 2019·Endocrine Reviews·Johannes HoflandWouter W de Herder
Jun 1, 1992·Scandinavian Journal of Gastroenterology·J E GrønbechA Bergan
May 1, 1991·Scandinavian Journal of Gastroenterology·F KolmannskogL E Hanssen
Jun 1, 1986·Anaesthesia·K Houghton, J A Carter
Dec 24, 2003·Acta Oncologica·Isac I SchnirerJaffer A Ajani
Sep 1, 1993·Seminars in Surgical Oncology·J G McKinnon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.